OSR (NASDAQ:OSRH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of OSR (NASDAQ:OSRH) to a sell rating in a research report sent to investors on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of OSR in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, OSR currently has an average rating of “Sell”.

OSR Stock Performance

NASDAQ:OSRH opened at $0.72 on Friday. OSR has a 52-week low of $0.45 and a 52-week high of $13.40. The stock’s 50 day moving average price is $0.63 and its 200 day moving average price is $1.03.

OSR (NASDAQ:OSRH) last posted its quarterly earnings data on Thursday, August 14th. The company reported $0.02 earnings per share for the quarter. The firm had revenue of $1.14 million during the quarter.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.